# Fast track designation

> An FDA designation that speeds development of drugs for serious conditions with unmet need, adding FDA contact and rolling review of the application.

Source: https://www.quantisnow.com/glossary/fast-track
Topic: Glossary / Biotech and FDA
Also known as: fast track, FDA fast track, fast track status
Last updated: 2026-10-27

Fast track designation is an FDA program that expedites development and review of drugs intended to treat serious conditions and fill an unmet medical need. It is the most common of the FDA's expedited programs and can be granted early in development.

## How it works

A sponsor can request fast track at any time after submitting an [IND](https://www.quantisnow.com/glossary/ind), and the FDA responds within 60 days. To qualify, a drug must target a serious condition and show the potential to address an unmet need, which can be supported by nonclinical or early clinical data. "Unmet need" covers conditions with no therapy as well as cases where the drug may be better than existing options, for example on efficacy, safety or reduced side effects.

Benefits include:

- More frequent meetings and written communication with the FDA.
- **Rolling review:** the sponsor can submit completed sections of its [NDA](https://www.quantisnow.com/glossary/nda) or BLA as they are ready, rather than waiting to file everything at once.
- Eligibility for [priority review](https://www.quantisnow.com/glossary/priority-review) and [accelerated approval](https://www.quantisnow.com/glossary/accelerated-approval) if criteria are met.

The FDA can withdraw the designation if the drug no longer meets the criteria.

## Why it matters for traders

Fast track headlines are frequent, especially from small-cap biotechs, and often produce a brief pop. Because the bar is lower than [breakthrough therapy designation](https://www.quantisnow.com/glossary/breakthrough-therapy), the market usually treats it as a modest positive: it confirms the target disease is serious and may shave time off the filing, but says little about whether the drug works.

## Example

Northwind Therapeutics (NWTX) has an IND in effect for a drug targeting a rare kidney disease with no approved treatments. Based on animal data, it requests fast track and receives it 58 days later. Two years on, it uses rolling review to submit the nonclinical and manufacturing modules of its NDA months before the clinical data are complete.

## FAQ

### Does fast track mean the drug will be approved faster?

It can shorten the overall timeline through rolling review and more FDA interaction, but the approval standard does not change.

### How is fast track different from priority review?

Fast track applies during development and filing. Priority review sets a shorter 6-month review clock once an application is accepted.

## Related terms

- [Breakthrough therapy designation](https://www.quantisnow.com/glossary/breakthrough-therapy.md): An FDA designation that speeds development of a drug for a serious condition when early clinical data show substantial improvement over existing therapy.
- [Priority review](https://www.quantisnow.com/glossary/priority-review.md): An FDA designation that shortens the review goal for a drug application to 6 months instead of the standard 10 months.
- [Accelerated approval](https://www.quantisnow.com/glossary/accelerated-approval.md): An FDA pathway approving drugs for serious conditions based on a surrogate endpoint, with confirmatory trials required to verify clinical benefit.
- [Orphan drug designation](https://www.quantisnow.com/glossary/orphan-drug-designation.md): An FDA status for drugs treating rare diseases affecting fewer than 200,000 people in the US, bringing incentives such as 7 years of market exclusivity.
- [Investigational New Drug application (IND)](https://www.quantisnow.com/glossary/ind.md): The FDA filing a sponsor must have in effect before testing an unapproved drug or biologic in humans in the United States.
- [New Drug Application (NDA)](https://www.quantisnow.com/glossary/nda.md): The formal application a drugmaker submits to the FDA requesting approval to market a new small-molecule drug in the United States.

## On Quantisnow

- [FDA approval process](https://www.quantisnow.com/guides/fda-approval-process)
- [Live feed: FDA Approvals](https://www.quantisnow.com/news/fda)
